Pabst Patent Group LLP
Predictive biomarkers for CTLA-4 blockade therapy and for PD-1 blockade therapy
Biomarkers are described for predicting the efficacy, risk of relapse, risk of an immune related adverse event (irAE), or combination thereof for a CTLA-4 blockade treatment, such as ipilimumab, in a subject with melanoma. Biomarkers are also described for predicting the efficacy and clinical benefit for a PD-1 blockade treatment, such as a PD-1 blocking antibody, in a subject with melanoma.
H. Lee Moffitt Cancer and Research Institute, Inc.
G G A G C G C C G
G01N G01N A61K G01N C07K G01N C07K C07K G01N
additional inventional additional inventional inventional additional additional inventional inventional
Jeffrey S. Bin Wenshi
Weber Yu Wang